GlassScriptPhysician profile
Humaira Hashmi
NPI 1699938837
$5,889.89
in general payments reported to CMS, 2019-2025
21 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what 83% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $489 · 2021: $1,134 · 2022: $856 · 2023: $934 · 2024: $1,002 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,117.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,748.61 | 2021-2025 | Stelara, Tremfya |
| Abbvie INC. | $1,680.31 | 2019-2025 | |
| Qol Medical, LLC | $1,198.73 | 2019-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $216.43 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $202.78 | 2020-2023 | |
| Pfizer INC. | $143.28 | 2019-2021 | |
| Sandoz INC. | $111.47 | 2023-2024 | Hyrimoz |
| Mirum Pharmaceuticals, INC. | $102.57 | 2022-2025 | Livmarli, Chenodal, Cholbam |
| Regeneron Healthcare Solutions, INC. | $80.91 | 2023-2025 | Dupixent |
| Amgen INC. | $80.52 | 2021-2025 | Actimmune |
| Celgene Corporation | $55.68 | 2023-2024 | Zeposia |
| Travere Therapeutics, INC. | $51.66 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $35.50 | 2019-2021 | |
| Alfasigma USA, INC. | $33.12 | 2021 | |
| Cook Medical LLC | $27.09 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $24.26 | 2024 | |
| Cumberland Pharmaceuticals, INC. | $20.89 | 2024 | Kristalose |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.58 | 2023 | Cyltezo |
| Takeda Pharmaceuticals U.S.A., INC. | $20.26 | 2024 | Eohilia |
| Novo Nordisk INC | $17.82 | 2024 | Wegovy |
| Kadmon Pharmaceuticals LLC | $17.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humaira Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.